Mayo Clinic researchers have shed light on a new mechanism by which prostate cancer develops in men. Central to development of nearly all prostate cancer cases are malfunctions in the androgen receptor—the cellular component ...
Feb 10, 2014
0
0
Dr. Karen Tordjman, a senior lecturer at Tel Aviv University's Sackler Faculty of Medicine didn't have an immediate diagnosis for the under-masculinized young man who walked into her office. A 25-year-old university student ...
Oct 11, 2013
0
0
Prostate cancer is one of the most common forms of cancer in men and the leading cause of cancer deaths in white, African-American and Hispanic men, according to the Centers for Disease Control. Current treatment of prostate ...
Aug 20, 2013
0
0
A team of researchers from UC Davis, UC San Diego and other institutions has identified a key mechanism behind aggressive prostate cancer. Published on August 14, 2013 in Nature, the study shows that two long non-coding RNAs ...
Aug 14, 2013
0
0
(Medical Xpress)—For the past 70 years, androgen deprivation therapy (ADT) has been the standard treatment for men diagnosed with late-stage prostate cancer.
Jun 14, 2013
0
0
Researchers at the University of Adelaide are spearheading a new direction in prostate cancer research, with the potential for new treatments of the disease.
Jun 3, 2013
0
0
Dr. Jung-Mo Ahn, associate professor of chemistry at The University of Texas at Dallas, has designed and synthesized a novel small molecule that might become a large weapon in the fight against prostate cancer.
May 28, 2013
0
5
A new study on prostate cancer describes a novel class of drugs developed by UT Southwestern Medical Center researchers that interrupts critical signaling needed for prostate cancer cells to grow.
May 28, 2013
0
0
Estrogen and progesterone receptors, and the gene HER2 – these are the big three markers and/or targets in breast cancer. Evidence presented at the AACR Annual Meeting 2013 adds a fourth: androgen receptors.
Apr 10, 2013
0
0
Non-invasive 'liquid biopsies' can find metastatic or recurrent prostate cancer, in a low cost assay suitable for most healthcare systems, finds research published in BioMed Central's open access journal Genome Medicine. ...
Apr 4, 2013
0
0
